The Obesity Drug Development Summit has landed in Europe!

If you thought GLP-1 agonists were transformative - wait until you see what’s next.
The obesity drug market is exploding into a $100 billion opportunity, fuelled by breakthroughs in GLP-1 combinations, novel targets like GIPR modulators, and RNA-based therapies. However, with rapid innovation come critical challenges: efficacy gaps, lean mass preservation, payer demands, and manufacturing bottlenecks.
The Obesity Drug Development Summit Europe is your perfect platform to be in a prime position to be at the forefront of this movement and shape the future of obesity care.
Dates: 1st-2nd October, 2025
Venue: Hilton Barcelona, Spain
Website: https://ter.li/yko2cd
Join 50+ industry leaders from Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and pioneering biotechs in sunny Barcelona this October to:
- Explore GIPR agonism/antagonism, mitochondrial activators, and DNA-encoded therapies to achieve obesity treatments for true metabolic transformation.
- Design payer-winning trials to leverage real-world evidence, precision biomarkers, and patient-centric endpoints to optimise clinical trial design and market access acceleration.
- Advanced combination therapies & formulations to preserve lean mass, improve tolerability, and overcome delivery challenges to improve patient adherence.
- Navigate the $100B opportunity to position your pipeline at the forefront of this revolution and establish leadership in the cardiometabolic drug revolution.
Get your copy of the event guide to explore the full speaker and sessions lineup: https://ter.li/yko2cd
Ready to make your mark on the obesity drugs landscape? Head to our online registration page to take advantage of our most competitive rates and group packages: https://ter.li/gk6pzn